Hadassah

Hadassah Collaborates with Columbia University to Identify Treatment for Alopecia

Friday, Jun 5 2015

Working in collaboration with Columbia University, a team of Hadassah Medical Organization physicians have discovered that an arthritis medication may be the solution to baldness caused by alopecia.

The researchers have found that Baricitinib, a medicine in development for treatment of rheumatoid arthritis, may prove effective for severe Alopecia Areata (AA), a common autoimmune disease which causes sudden or gradual hair loss. "Despite its high prevalence," the team reports, "there are no Food and Drug Administration-approved treatments for AA."

The team, including Hadassah Dermatologist Dr. Yuval Ramot, Prof. Abraham Zlotogorski, Director of Hadassah Hospital Ein Kerem's Department of Dermatology and its Hair Loss Clinic, and Prof. Yackov Berkun of Hadassah Hospital Mount Scopus' Pediatric Unit, has found the medicine to be effective in both animals and humans.

"This discovery opens a variety of options for future treatment of AA," notes Dr. Ramot. "That said, extensive clinical trials are still needed in order to fully confirm the findings, before marketing these new medications for treatment of AA."

The research team hopes to begin such clinical trials in the near future. The present study is highlighted in the April 2015 issue of EBioMedicine.

Comments

From: Marjorie on June 6, 2015
I believe I would be a candidate for these clinical trials. Please contact me.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›
alt_text

Tuesday, Apr 17 2018

Predicting Clinical Outcomes for Multiple Sclerosis Patients: Cutting-Edge Research at Hadassah

More than two million people--two to three times more women--have multiple sclerosis (MS)--the leading cause of neurological disability among young adults. What is their prognosis?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More